[go: up one dir, main page]

NO20003600L - Kalium kanal inhibitorer - Google Patents

Kalium kanal inhibitorer

Info

Publication number
NO20003600L
NO20003600L NO20003600A NO20003600A NO20003600L NO 20003600 L NO20003600 L NO 20003600L NO 20003600 A NO20003600 A NO 20003600A NO 20003600 A NO20003600 A NO 20003600A NO 20003600 L NO20003600 L NO 20003600L
Authority
NO
Norway
Prior art keywords
potassium channel
channel inhibitors
inhibitors
treatment
cell proliferative
Prior art date
Application number
NO20003600A
Other languages
English (en)
Norwegian (no)
Other versions
NO20003600D0 (no
Inventor
Michael F Gross
Neil A Castle
Original Assignee
Icagen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Icagen Inc filed Critical Icagen Inc
Publication of NO20003600D0 publication Critical patent/NO20003600D0/no
Publication of NO20003600L publication Critical patent/NO20003600L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
    • C07C311/12—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing rings
    • C07C311/13—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing rings the carbon skeleton containing six-membered aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/20—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/22—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
    • C07C311/28—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/40—Acylated substituent nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/50—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to atoms of the carbocyclic ring
    • C07D317/60—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/10—One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Magnetic Heads (AREA)
  • Pyridine Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Seasonings (AREA)
  • Sorption Type Refrigeration Machines (AREA)
  • External Artificial Organs (AREA)
NO20003600A 1998-01-27 2000-07-13 Kalium kanal inhibitorer NO20003600L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7271998P 1998-01-27 1998-01-27
PCT/US1999/001663 WO1999037607A1 (fr) 1998-01-27 1999-01-27 Inhibiteurs des canaux de potassium

Publications (2)

Publication Number Publication Date
NO20003600D0 NO20003600D0 (no) 2000-07-13
NO20003600L true NO20003600L (no) 2000-09-26

Family

ID=22109343

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20003600A NO20003600L (no) 1998-01-27 2000-07-13 Kalium kanal inhibitorer

Country Status (21)

Country Link
US (1) US6333337B1 (fr)
EP (1) EP1051394B1 (fr)
JP (1) JP2002501041A (fr)
KR (1) KR20010034377A (fr)
CN (1) CN1294577A (fr)
AT (1) ATE265426T1 (fr)
AU (1) AU745845B2 (fr)
BR (1) BR9907236A (fr)
CA (1) CA2317457A1 (fr)
DE (1) DE69916792D1 (fr)
HU (1) HUP0101269A3 (fr)
ID (1) ID25853A (fr)
IL (1) IL137219A0 (fr)
NO (1) NO20003600L (fr)
NZ (1) NZ505666A (fr)
PL (1) PL341859A1 (fr)
RU (1) RU2218330C2 (fr)
TR (1) TR200002191T2 (fr)
TW (1) TW542823B (fr)
WO (1) WO1999037607A1 (fr)
ZA (1) ZA99550B (fr)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6333349B1 (en) * 1997-02-26 2001-12-25 Aventis Pharma Deutschland Gmbh Sulfonamide-substituted fused 7-membered ring compounds, their use as a medicament, and pharmaceutical preparations comprising them
CA2341678C (fr) 1998-09-01 2009-10-13 Bristol-Myers Squibb Company Inhibiteurs de canaux potassium et leur methode d'utilisation
WO2001021648A1 (fr) * 1999-09-22 2001-03-29 Cognetix, Inc. Utilisation de la kappa-conotoxine pviia
JP2003518101A (ja) * 1999-12-21 2003-06-03 アイカゲン インコーポレイテッド カリウムチャネル阻害剤
US6566380B2 (en) * 2000-07-25 2003-05-20 Icagen, Inc. Potassium channel inhibitors
US6620849B2 (en) 2000-07-26 2003-09-16 Icafen, Inc. Potassium channel inhibitors
DE10059418A1 (de) 2000-11-30 2002-06-20 Aventis Pharma Gmbh Ortho, meta-substituierte Bisarylverbindungen, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament sowie sie enthaltende pharmazeutische Zubereitungen
DE10060807A1 (de) 2000-12-07 2002-06-20 Aventis Pharma Gmbh Ortho, ortho-substituierte stickstoffhaltige Bisarylverbindungen, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament sowie sie enthaltende pharmazeutische Zubereitungen
DE10061876A1 (de) * 2000-12-12 2002-06-20 Aventis Pharma Gmbh Arylierte Furan- und Thiophencarbonsäureamide, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament sowie sie enthaltende pharmazeutische Zubereitungen
US6849634B2 (en) 2000-12-21 2005-02-01 Icagen Potassium channel inhibitors
DE10121003A1 (de) 2001-04-28 2002-12-19 Aventis Pharma Gmbh Anthranilsäureamide, Verfahren zur Herstellung, ihrer Verwendung als Medikament sowie sie enthaltende pharmazeutische Zubereitungen
US7470518B2 (en) 2002-02-12 2008-12-30 Cellectricon Ab Systems and method for rapidly changing the solution environment around sensors
EP2368636A3 (fr) 2002-02-12 2012-03-07 Cellectricon Ab Systèmes et procédés de changement rapide de l'environnement de solution autour de capteurs
US20030199578A1 (en) * 2002-04-19 2003-10-23 Turner Sean C. Naphthalene amides as potassium channel openers
BR0309940A (pt) * 2002-05-08 2005-02-09 Bayer Healthcare Ag Derivados de hidróxi-tetraidro-naftaleniluréia
WO2004052846A1 (fr) * 2002-12-06 2004-06-24 Bayer Healthcare Ag Derives de tetrahydro-naphthalene
ATE404531T1 (de) * 2002-12-09 2008-08-15 Xention Ltd Tetrahydronaphtalen-derivate als vanilloid- rezeptor-antagonisten
GB0315950D0 (en) 2003-06-11 2003-08-13 Xention Discovery Ltd Compounds
EA010186B1 (ru) 2003-10-08 2008-06-30 Шеринг Акциенгезельшафт Производные тетрагидронафталина, способ их получения и их применение в качестве противовоспалительных средств
US7638515B2 (en) 2003-10-08 2009-12-29 Bayer Schering Pharma Aktiengesellschaft Tetrahydronaphthalene derivatives, process for their production and their use as anti-inflammatory agents
US7662821B2 (en) 2003-10-08 2010-02-16 Bayer Schering Pharma Ag Tetrahydronaphthalene derivatives, process for their production and their use as anti-inflammatory agents
US20080153859A1 (en) 2004-04-05 2008-06-26 Hartmut Rehwinkel Multiply-substituted tetrahydronaphthalene derivatives, process for their production and their use as anti-inflammatory agents
GB0412986D0 (en) 2004-06-10 2004-07-14 Xention Discovery Ltd Compounds
US7576212B2 (en) 2004-12-09 2009-08-18 Xention Limited Thieno[2,3-B] pyridines as potassium channel inhibitors
DE102005017316A1 (de) * 2005-04-14 2006-10-19 Schering Ag Tetrahydronaphthalinderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Entzündungshemmer
GB0525164D0 (en) 2005-12-09 2006-01-18 Xention Discovery Ltd Compounds
EP1834948A1 (fr) 2006-03-15 2007-09-19 Bayer Schering Pharma Aktiengesellschaft Derives de tetrahydronaphtalene , procedes pour leur production et leur utilisation en tant qu'anti-inflammatoires
RU2008144805A (ru) * 2006-04-14 2010-05-20 Новартис АГ (CH) Применение биарилкарбоксамидов в лечении заболеваний, связанных с hedgehog-путем
DE102006019589A1 (de) * 2006-04-27 2007-10-31 Sanofi-Aventis Deutschland Gmbh Inhibitoren des TASK-1 und Task-3 Ionenkanals
JP5419691B2 (ja) * 2006-08-23 2014-02-19 バレアント ファーマシューティカルズ インターナショナル カリウムチャネルモジュレーターとしての４−（ｎ−アザシクロアルキル）アニリドの誘導体
AU2007325629A1 (en) * 2006-11-28 2008-06-05 Valeant Pharmaceuticals International 1,4 diamino bicyclic retigabine analogues as potassium channel modulators
GB0815782D0 (en) 2008-08-29 2008-10-08 Xention Ltd Novel potassium channel blockers
GB0815781D0 (en) 2008-08-29 2008-10-08 Xention Ltd Novel potassium channel blockers
GB0815784D0 (en) 2008-08-29 2008-10-08 Xention Ltd Novel potassium channel blockers
GB201105659D0 (en) 2011-04-01 2011-05-18 Xention Ltd Compounds
NO3175985T3 (fr) 2011-07-01 2018-04-28
CA2862670A1 (fr) 2012-01-27 2013-08-01 Gilead Sciences, Inc. Therapies de combinaison a l'aide de bloqueurs de canaux ioniques au sodium tardifs et de bloqueurs de canaux ioniques au potassium
CA3151863C (fr) 2021-10-27 2024-01-02 Shanghai Zhimeng Biopharma, Inc. Compose comme regulateur de canal de potassium et preparation et utilisation connexes

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3953506A (en) 1974-02-07 1976-04-27 American Cyanamid Company Ureidotetralin compounds
US4005140A (en) 1974-02-07 1977-01-25 American Cyanamid Company Ureidotetralin compounds
GB1479544A (en) 1974-02-07 1977-07-13 American Cyanamid Co 1,2,3,4-tetrahydro-1-naphthylurea derivatives their preparation and their use
GB8707123D0 (en) 1987-03-25 1987-04-29 Pfizer Ltd Antiarrhythmic agents
US5006512A (en) 1987-10-02 1991-04-09 Tsuyoshi Ohnishi Therapeutic usages of inhibitors for a potassium efflux channel
IL88314A (en) 1987-11-18 1994-05-30 Tanabe Seiyaku Co Sulphonylamino indane derivatives, their preparation and pharmaceutical compositions containing them
AU609232B2 (en) 1987-12-14 1991-04-26 Beecham Group Plc Novel indane derivatives possessing smooth muscle relaxant activity
US5242947A (en) 1988-02-10 1993-09-07 New York University Use of polyamines as ionic-channel regulating agents
DE3818245A1 (de) 1988-05-28 1989-12-07 Hoechst Ag Kombination von angiotensin-converting-enzyme-hemmern mit kaliumkanal-modulatoren sowie deren verwendung in arzneimitteln
ES2123500T3 (es) * 1989-05-31 1999-01-16 Upjohn Co Derivados de 8-heterociclil-2-aminotetralina activos sobre el sistema nervioso central.
US5215985A (en) 1990-07-20 1993-06-01 E. R. Squibb & Sons, Inc. Method for treating ischemic insult to neurons employing an ATP-sensitive potassium channel blocker
EP0472053B1 (fr) 1990-08-20 1998-06-17 Eisai Co., Ltd. Dérivés de sulfonamide
US5401848A (en) 1990-11-26 1995-03-28 E. R. Squibb & Sons, Inc. Indane and quinoline derivatives
US5310932A (en) 1991-04-15 1994-05-10 E. R. Squibb & Sons, Inc. Chromanyl substituted indole potassium channel openers
US5234947A (en) 1991-11-07 1993-08-10 New York University Potassium channel activating compounds and methods of use thereof
US5356775A (en) 1992-07-29 1994-10-18 Brigham & Women's Hospital Primary structure for functional expression from complementary DNA of a mammalian ATP-sensitive potassium channel
US5328830A (en) 1992-09-08 1994-07-12 Miles Inc. Potassium channel modulators
US5374643A (en) 1992-09-11 1994-12-20 E. R. Squibb & Sons, Inc. Aryl urea (thiourea) and cyanoguanidine derivatives
US5453421A (en) 1992-09-11 1995-09-26 E. R. Squibb & Sons, Inc. Aryl and heterocyclic substituted propenamide derivatives
DE4302051A1 (de) 1993-01-26 1994-07-28 Thomae Gmbh Dr K 5-gliedrige Heterocyclen, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
GB9309716D0 (en) 1993-05-12 1993-06-23 Zeneca Ltd Heterocyclic derivatives
US5401758A (en) 1993-10-07 1995-03-28 Bristol-Myers Squibb Company Pyridinyl cyanoguanidine compounds
US5631275A (en) 1993-12-30 1997-05-20 Hoechst Aktiengesellschaft Substituted benzenesulfonylureas and -thioureas, preparation processes and possible uses of pharmaceutical preparations based on these compounds
FR2717805B1 (fr) 1994-03-28 1996-05-10 Rhone Poulenc Rorer Sa Dérivés de 5H-indeno[1,2-b]pyrazine-2,3-dione, leur préparation et les médicaments les contenant .
US5615460A (en) 1994-06-06 1997-04-01 The Procter & Gamble Company Female component for refastenable fastening device having regions of differential extensibility
ZA96211B (en) 1995-01-12 1996-07-26 Teva Pharma Compositions containing and methods of using 1- aminoindan and derivatives thereof and process for preparing optically active 1-aminoindan derivatives
WO1996036596A1 (fr) 1995-05-19 1996-11-21 Chiroscience Limited 3,4-phenylsulfamides disubstitues et leur utilisation therapeutique
AU1582197A (en) 1996-01-22 1997-08-11 Eli Lilly And Company Combinatorial process for preparing substituted indane libraries
US6083986A (en) 1996-07-26 2000-07-04 Icagen, Inc. Potassium channel inhibitors
US6048877A (en) 1997-02-21 2000-04-11 Bristol-Myers Squibb Company Tetralone derivatives as antiarrhythmic agents

Also Published As

Publication number Publication date
AU745845B2 (en) 2002-04-11
HUP0101269A3 (en) 2003-01-28
KR20010034377A (ko) 2001-04-25
EP1051394B1 (fr) 2004-04-28
CN1294577A (zh) 2001-05-09
US6333337B1 (en) 2001-12-25
PL341859A1 (en) 2001-05-07
NO20003600D0 (no) 2000-07-13
ID25853A (id) 2000-11-09
AU2241999A (en) 1999-08-09
TR200002191T2 (tr) 2000-11-21
NZ505666A (en) 2002-11-26
TW542823B (en) 2003-07-21
DE69916792D1 (de) 2004-06-03
BR9907236A (pt) 2002-01-22
JP2002501041A (ja) 2002-01-15
RU2218330C2 (ru) 2003-12-10
ATE265426T1 (de) 2004-05-15
ZA99550B (en) 1999-07-26
IL137219A0 (en) 2001-07-24
WO1999037607A1 (fr) 1999-07-29
HUP0101269A1 (hu) 2001-10-28
EP1051394A1 (fr) 2000-11-15
CA2317457A1 (fr) 1999-07-29

Similar Documents

Publication Publication Date Title
NO20003600L (no) Kalium kanal inhibitorer
ATE250571T1 (de) Kaliumkanal-blocker
DE69924135D1 (de) Heterozyklische kalium-kanal inhibitoren
TR200100922T2 (tr) Aktif maddelerin akciğerler yolu ile tatbik edilmesi.
DE60108754D1 (de) Substituierte bizyklische derivate für die behandlung von unnormalem zellwachstum
AU5624699A (en) Use of 5ht-6 antagonists
BG104780A (en) Inhibitors of phospholipase enzymes
NZ506329A (en) Inhibitors of phospholipase enzymes
PT1214936E (pt) Utilizacao de derivados de tiazolidina ou pirrolidina de aminoacidos como agentes anti-hiperglicemicos
SG148834A1 (en) Compounds for the modulation of ppary activity
YU40203A (sh) Orto-supstituisana bis-aril jedinjenja, koja sadrže azot, primenjena kao inhibitori kalijumovog kanala
IS6950A (is) Samsetning epóþílonhliðstæðna og efnameðferðarlyfja til meðhöndlunar frumufjölgunarsjúkdóma
MY135766A (en) Quinolinones and naphthyridinones for treating inflammatory diseases
EP1143965A4 (fr) Inhibiteurs carbocycliques des canaux de potassium
ES2170252T3 (es) Tetrahidroimidazopiridoindoldionas como inhibidores de cgmp especifico pde.
PT1325011E (pt) Metodos e compostos para tratamento de doencas proliferativas
ATE549024T1 (de) Chinazolin-kaliumkanalhemmer
DE602004028493D1 (de) Isochinolinon-kaliumkanalinhibitoren
NO20052267L (no) Forbindelser, Preparater og Metoder
AR022321A1 (es) Derivados de anticonvulsivo utiles para el tratamiento de la migrana transformada
TR200002203T2 (tr) Lemfotoksin (LT) sentezlenme yolunun inhibitörleri kullanılarak foliküler lemfomaların tedavisi.
ECSP003590A (es) Compuestos calcioliticos
ECSP034604A (es) Inhibicion de la dependendia de celulas tumorales del factor de crecimiento
EA200300468A1 (ru) Подавление зависимости опухолевых клеток от фактора роста
IL139144A0 (en) Mycobacterial inhibitors